Perioperative	B:C0150706
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	B:C4013784
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	B:C0751429
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	B:C0031511
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	B:C0031511
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	B:C1325901
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	B:C0282607
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	O
cell	I:C0376604
.	O

Perioperative	O
Management	I:C0150706
of	O
Severe	O
Hypertension	I:C4013784
during	O
Laparoscopic	O
Surgery	I:C0751429
for	O
Pheochromocytoma	O
Phaeochromocytoma	O
is	O
a	O
catecholamine	O
-	I:C1325901
secreting	I:C1325901
vascular	O
tumour	I:C0282607
that	O
is	O
derived	O
from	O
chromaffin	B:C0376604
cell	I:C0376604
.	O

Lethal	B:C3151529
cardiovascular	O
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	O
,	O
myocardial	O
infarction	I:C0027051
and	O
aortic	O
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	O
catecholamine	I:C0271748
release	I:C0271748
.	O

Lethal	O
cardiovascular	B:C0161816
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	O
,	O
myocardial	O
infarction	I:C0027051
and	O
aortic	O
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	O
catecholamine	I:C0271748
release	I:C0271748
.	O

Lethal	O
cardiovascular	O
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	B:C0020538
,	O
myocardial	O
infarction	I:C0027051
and	O
aortic	O
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	O
catecholamine	I:C0271748
release	I:C0271748
.	O

Lethal	O
cardiovascular	O
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	O
,	O
myocardial	B:C0027051
infarction	I:C0027051
and	O
aortic	O
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	O
catecholamine	I:C0271748
release	I:C0271748
.	O

Lethal	O
cardiovascular	O
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	O
,	O
myocardial	O
infarction	I:C0027051
and	O
aortic	B:C0340643
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	O
catecholamine	I:C0271748
release	I:C0271748
.	O

Lethal	O
cardiovascular	O
complications	I:C0161816
,	O
such	O
as	O
serious	O
hypertension	O
,	O
myocardial	O
infarction	I:C0027051
and	O
aortic	O
dissection	I:C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B:C0271748
catecholamine	I:C0271748
release	I:C0271748
.	O

Each	O
stage	O
of	O
anaesthesia	B:C1300200
management	I:C1300200
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	O
catecholamine	I:C0271748
secretion	I:C0271748
that	O
may	O
occur	O
during	O
induction	O
,	O
perioperative	O
stage	O
and	O
surgical	O
manipulation	I:C0185111
.	O

Each	O
stage	O
of	O
anaesthesia	O
management	I:C1300200
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B:C0271748
catecholamine	I:C0271748
secretion	I:C0271748
that	O
may	O
occur	O
during	O
induction	O
,	O
perioperative	O
stage	O
and	O
surgical	O
manipulation	I:C0185111
.	O

Each	O
stage	O
of	O
anaesthesia	O
management	I:C1300200
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	O
catecholamine	I:C0271748
secretion	I:C0271748
that	O
may	O
occur	O
during	O
induction	B:C0857127
,	O
perioperative	O
stage	O
and	O
surgical	O
manipulation	I:C0185111
.	O

Each	O
stage	O
of	O
anaesthesia	O
management	I:C1300200
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	O
catecholamine	I:C0271748
secretion	I:C0271748
that	O
may	O
occur	O
during	O
induction	O
,	O
perioperative	O
stage	O
and	O
surgical	B:C0185111
manipulation	I:C0185111
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B:C0150706
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	B:C3536752
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	B:C3536830
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	B:C0037533
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	B:C0246631
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	B:C0751429
surgery	I:C0751429
for	O
phaeochromocytoma	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	O
preparation	I:C0150706
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α-	O
adrenergic	I:C3536752
blockade	I:C3536752
,	O
β-	O
adrenergic	I:C3536830
blockade	I:C3536830
,	O
sodium	O
nitroprusside	I:C0037533
and	O
remifentanil	O
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	O
surgery	I:C0751429
for	O
phaeochromocytoma	B:C0031511
.	O

